Entrada Therapeutics, Inc. (TRDA)
NASDAQ: TRDA · Real-Time Price · USD
7.74
+0.59 (8.25%)
At close: Jun 26, 2026, 4:00 PM EDT
7.60
-0.14 (-1.81%)
After-hours: Jun 26, 2026, 7:33 PM EDT

Entrada Therapeutics Stock Forecast

Stock Price Forecast

According to 8 analysts polled by S&P Global, Entrada Therapeutics stock has a consensus rating of "Strong Buy" and an average price target of $18.75. The average 1-year stock price forecast is 142.25% higher than the current stock price, while the lowest is $10 (+29.20%) and the highest is $25 (+223.00%).

Price Target: $18.75 (+142.25%)
Analyst Consensus: Strong Buy
TargetLowAverageMedianHigh
Price$10$18.75$20$25
Change+29.20%+142.25%+158.40%+223.00%

Analyst Ratings

The average analyst rating for Entrada Therapeutics stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.

Recommendation Trends

RatingJan '26Feb '26Mar '26Apr '26May '26Jun '26
Strong Buy677877
Buy000000
Hold000011
Sell000000
Strong Sell000000
Total677888

Latest Forecasts

AnalystFirmRatingRatingActionPrice TargetUpsideDate
Guggenheim
Guggenheim
Buy
Maintains
$20$17
BuyMaintains$20$17+119.64%Jun 5, 2026
Oppenheimer
Oppenheimer
Buy
Reiterates
$23
BuyReiterates$23+197.16%Jun 3, 2026
Roth MKM
Roth MKM
Buy
Reiterates
$6.64$10
BuyReiterates$6.64$10+29.20%Jun 3, 2026
H.C. Wainwright
H.C. Wainwright
Hold
Downgrades
n/a
HoldDowngradesn/an/aMay 8, 2026
TD Cowen
TD Cowen
Buy
Maintains
n/a
BuyMaintainsn/an/aMay 7, 2026
More Analyst Ratings

Financial Forecast

Revenue This Year
14.99M
from 25.42M
Decreased by -41.04%
Revenue Next Year
29.81M
from 14.99M
Increased by 98.87%
EPS This Year
-3.79
from -3.47
EPS Next Year
-3.26
from -3.79
Fiscal YearFY 2021FY 2022FY 2023FY 2024FY 2025FY 2026
Period EndingDec 31, 2021Dec 31, 2022Dec 31, 2023Dec 31, 2024Dec 31, 2025Dec 31, 2026
Revenue
--129.01M210.78M25.42M14.99M
Revenue Growth
---63.38%-87.94%-41.04%
Gross Profit
-35.93M-66.61M29.13M85.48M-115.15M14.99M
Gross Margin
--22.58%40.55%-452.96%100.00%
Operating Income
-51.13M-97.25M-3.16M47.01M-156.00M-180.48M
Net Income
-51.16M-94.62M-6.69M65.63M-143.75M-175.84M
EPS
-----3.47-3.79
Free Cash Flow
-36.26M-58.56M149.04M-73.29M-76.96M-180.61M
No. Analysts
-----7
EPS and Forward PE are based on non-GAAP adjusted numbers.

Revenue Forecast

Revenue202620272028
High60.0M
Avg15.0M
Low875,000

Revenue Growth

Revenue Growth202620272028
High
136.0%
Avg
-41.0%
Low
-96.6%

EPS Forecast

EPS202620272028
High-2.68
Avg-3.79
Low-4.49

EPS Growth

EPS Growth202620272028
High-
Avg-
Low-